Post-treatment surveillance imaging in lymphoma
Appropriate post-treatment management of patients with lymphoma has been controversial, with imaging frequently performed as post-treatment surveillance. The goal of post-treatment imaging is to identify relapse prior to clinical symptoms, when the burden of disease is lower and the possibility of effective salvage therapy and cure are greater. However, little data exist to support the performance of surveillance imaging after completion of treatment, with the vast majority of studies suggesting there is no clinical benefit to surveillance imaging in asymptomatic patients. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Susan M. Hiniker, Richard T. Hoppe Source Type: research
Cell-Free DNA as a Post-Treatment Surveillance Strategy: Current Status
Circulating tumor DNA (ctDNA) consists of cell-free DNA (cfDNA) fragments that are released from tumor cells into the bloodstream. ctDNA harbors cancer-specific genetic and epigenetic alterations that allow its detection and quantification using a variety of emerging techniques. The promise of convenient non-invasive access to the complex and dynamic molecular features of cancer through peripheral blood has galvanized translational researchers around this topic with compelling routes to clinical implementation, particularly in the post-treatment surveillance setting. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Justin M. Burgener, Arianna Rostami, Daniel D. De Carvalho, Scott V. Bratman Source Type: research
Post-Treatment Surveillance Imaging in Lymphoma
Appropriate post-treatment management of patients with lymphoma has been controversial, with imaging frequently performed as post-treatment surveillance. The goal of post-treatment imaging is to identify relapse prior to clinical symptoms, when the burden of disease is lower and the possibility of effective salvage therapy and cure greater. However, little data exist to support the performance of surveillance imaging after completion of treatment, with the vast majority of studies suggesting there is no clinical benefit to surveillance imaging in asymptomatic patients. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Susan M. Hiniker, Richard T. Hoppe Source Type: research
An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma
Assessing response to therapy in lymphoma is important for determining patients ’ prognosis, guiding subsequent treatment, and may be used as an outcome measure of prognostic and therapeutic trials. Traditionally, computed tomography was the mainstay for response assessment and was predominantly performed at the end of treatment, whereas the most recent guidelines propose 18F -fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) for this purpose. However, the value of FDG-PET performed during treatment (interim FDG-PET) is still a topic of debate. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Hugo J.A. Adams, Thomas C. Kwee Source Type: research
Proteasome inhibitors: structure and function
Since 2003, the US Food and Drug Administration approval of bortezomib, a proteasome inhibitor, has changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Since that time, two additional proteasome inhibitors (carfilzomib and ixazomib) have been approved, with other agents and combinations currently under investigation. Proteasomes degrade ubiquitinated proteins or substrates through the ubiquitin-proteasome pathway, a pathway that is utilized in multiple myeloma because of the high protein turnover with immunoglobulin production. (...
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Ana T. Nunes, Christina M. Annunziata Source Type: research
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Cyclin dependent kinase (CDK) 4/6 inhibitors have advanced the treatment of metastatic breast cancer by targeting the cell cycle machinery, interrupting intracellular and mitogenic hormone signals that stimulate proliferation of malignant cells. Preclinical evidence demonstrated that derangements of cyclin D1, CDK4/6, and retinoblastoma expression are common in breast cancer, and suggested a therapeutic benefit from interrupting this axis required for cell cycle progression. Studies of cell lines and animal models of breast cancer have demonstrated the complex interplay between the cell cycle and estrogen receptor and huma...
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Susan Combs Scott, Sarah S. Lee, Jame Abraham Source Type: research
An Evidence-Based Review on the Value of Interim FDG-PET in Assessing Response to Therapy in Lymphoma
Assessing response to therapy in lymphoma is important for determining patients ’ prognosis, guiding subsequent treatment, and may be used as outcome measure of prognostic and therapeutic trials. Traditionally, computed tomography (CT) was the mainstay for response assessment and was predominantly performed at end of treatment, whereas the most recent guidelines propose 18F-f luoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) for this purpose. However, the value of FDG-PET performed during treatment (interim FDG-PET) is still a topic of debate. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Hugo J.A. Adams, Thomas C. Kwee Source Type: research
Proteasome Inhibitors: Structure and Function
Since 2003, with the FDA approval of bortezomib, proteasome inhibitors have changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Since that time, two additional proteasome inhibitors, carfilzomib and ixazomib have been approved, with other agents and combinations currently under investigation. Proteasomes degrade ubiquitinated proteins or substrates through the ubiquitin-proteasome pathway, a pathway that is utilized in multiple myeloma due to the high protein turnover with immunoglobulin production. (Source: Seminars in Oncology)
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Ana T. Nunes, Christina M. Annunziata Source Type: research
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Cyclin dependent kinase (CDK) 4/6 inhibitors have advanced the treatment of metastatic breast cancer by targeting the cell cycle machinery, interrupting intracellular and mitogenic hormone signals that stimulate proliferation of malignant cells. Preclinical evidence demonstrated that derangements of cyclin D1, CDK4/6 and retinoblastoma expression are common in breast cancer, and suggested a therapeutic benefit from interrupting this axis required for cell cycle progression. Studies of cell lines and animal models of breast cancer have demonstrated the complex interplay between the cell cycle and estrogen receptor (ER) and ...
Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Susan Combs Scott, Sarah S. Lee, Jame Abraham Source Type: research
The Surgical Management of Prostate Cancer
Prostate cancer is a heterogeneous disease with a variable natural history. Therefore, optimal management remains challenging. While many men with newly diagnosed prostate cancer may be candidates for active surveillance, there are others who will benefit from aggressive local therapy. Radical prostatectomy is associated with improvements in cancer-specific mortality, metastasis-free survival, and need for palliative treatments when compared with observation in several randomized controlled trials. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Elisabeth M. Sebesta, Christopher B. Anderson Source Type: research
The Surgical Management of Prostate Cancer
Prostate cancer is a heterogeneous disease with a variable natural history. Therefore, optimal management remains challenging. While many men with newly diagnosed prostate cancer may be candidates for active surveillance, there are others who will benefit from aggressive local therapy. Radical prostatectomy is associated with improvements in cancer-specific mortality, metastasis-free survival, and need for palliative treatments when compared to observation in several randomized controlled trials. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Elisabeth M. Sebesta, Christopher B. Anderson Source Type: research
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer in Korean population: A single-center cohort study
Pancreatic cancer has poor prognosis because of its rapid progression and treatment resistance. Based on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT), a combination regimen of gemcitabine with nab-paclitaxel is currently used as standard therapy for the treatment of metastatic pancreatic cancer. However, because studies in Asian populations are lacking, we investigated the treatment efficacy and safety of this combination therapy in Korean population. Patients with metastatic pancreatic cancer (n=81) treated with gemcitabine and nab-paclitaxel (1,000 and 125 mg/m2, respectively) as the fir...
Source: Seminars in Oncology - January 12, 2018 Category: Cancer & Oncology Authors: In Rae Cho, Huapyong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jae Bock Chung, Chansik An, Mi-Suk Park, So Young Jung, Seungmin Bang Source Type: research
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma
Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world. Front line treatment has shifted but ultimately has landed on a bortezomib-based combination therapy. Carfilzomib is a next-generation proteasome inhibitor shown to improve both progression-free and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd). Given the favorable response rates seen in phase II trials treating newly diagnosed myeloma, this combination is listed as a viable option for upfront treatment. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 12, 2018 Category: Cancer & Oncology Authors: Andrae Vandross Source Type: research
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer in Korean population: A single-center cohort study
Pancreatic cancer has poor prognosis due to its rapid progression and treatment resistance. Based on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT), a combination regimen of gemcitabine with nab-paclitaxel is currently used as standard therapy for metastatic pancreatic cancer. However, because studies in Asian populations are lacking, we investigated the treatment efficacy and safety of this combination therapy in a Korean population. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 12, 2018 Category: Cancer & Oncology Authors: In Rae Cho, Huapyong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jae Bock Chung, Chansik An, Mi-Suk Park, So Young Jung, Seungmin Bang Source Type: research
